CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in small molecules, TACS, glues and oligonucleotides CMC development to accelerate the delivery of life-changing medicines to patients. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements.
We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, separation science and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. In 2024, we acquired Reach Separations to offer expert end-to-end chromatographic support from discovery through launch, catering to full asset development or standalone projects.
Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world.
Recent recognition includes the 2024 Finance Awards Wales (ESG Excellence), the 2023 UK Fast Growth 50 Index Award (Innovative Growth) and the Queen’s Award for Enterprise: International Trade 2022.
